Food Science and Biotechnology

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지

The Hypoglycemic Effects of Acarviosine-Glucose Modulate Hepatic and Intestinal Glucose Transporters In vivo

  • Chung, Mi-Ja (Division of Food Science, College of Life Sciences and Biotechnology, Institute of Biomedical Sciences and Safety, Korea University) ;
  • Lee, Young-Soo (Center for Agricultural Biomaterials, Department of Food Science and Technology, School of Agricultural Biotechnology, Seoul National University) ;
  • Kim, Byoung-Chul (Division of Food Science, College of Life Sciences and Biotechnology, Institute of Biomedical Sciences and Safety, Korea University) ;
  • Lee, Soo-Bok (Research Institute of Food and Nutritional Sciences and Department of Food and Nutrition, Yonsei University) ;
  • Moon, Tae-Hwa (Center for Agricultural Biomaterials, Department of Food Science and Technology, School of Agricultural Biotechnology, Seoul National University) ;
  • Lee, Sung-Joon (Division of Food Science, College of Life Sciences and Biotechnology, Institute of Biomedical Sciences and Safety, Korea University) ;
  • Park, Kwan-Hwa (Center for Agricultural Biomaterials, Department of Food Science and Technology, School of Agricultural Biotechnology, Seoul National University)
  • Published : 2006.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Acarviosine-glucose (AcvGlc) is an ${\alpha}$-glucosidase inhibitor and has similar inhibitory activity to acarbose in vitro. We synthesized AcvGlc by treating acarbose with Bacillus stearothermophilus maltogenic amylase and fed C57BL/6J and db/db mice with diets containing purified AcvGlc and acarbose for 1 week. AcvGlc (50 and 100 mg/100 g diet) significantly reduced plasma glucose and triglyceride levels in db/db mice by 42 and 51 %, respectively (p<0.0001). The hypoglycemic and hypotriglyceridemic effects of AcvGlc were slightly, but significantly, greater than those seen with acarbose treatment (p<0.0001) in C57BL/6J mice. In an oral glucose tolerance test, glucose tolerance was significantly improved at all time points (p<0.01). The expression of two novel glucose transporters (GLUTs), GLUT10 and GLUT12, were examined by Western blot analysis. GLUT10 was markedly increased in the db/db livers. After AcvGlc treatment, the expression of hepatic GLUT10 was decreased whereas intestinal GLUT12 was significantly increased in both strains of mice. Our results show that AcvGlc improves plasma lipid and glucose metabolism slightly more than acarbose. Regulation of hepatic GLUT10 and intestinal GLUT12 may be important in controlling blood glucose levels.

Keywords

References

  1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37: 1595-1607 (1988) https://doi.org/10.2337/diabetes.37.12.1595
  2. Lefebvre PJ, Scheen AJ. The use of acarbose in the prevention and treatment of hypo glycaemia. Eur. J. Clin. Invest. 24 Suppl 3: 40-44 (1994)
  3. Chang AM, Smith MJ, Bloem CJ, Galecki AT, Halter ffi. Effect of lowering postgrandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance. Am. J. Physiol.-Endoc. M. 287: E906-911 (2004)
  4. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intimamedia thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35: 1073-1078 (2004) https://doi.org/10.1161/01.STR.0000125864.01546.f2
  5. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 359: 2072-2077 (2002) https://doi.org/10.1016/S0140-6736(02)08905-5
  6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial. J. Amer. Med. Assoc. 290: 486-494 (2003) https://doi.org/10.1001/jama.290.4.486
  7. Cheong KA, Kim TJ, Yoon JW, Park CS, Lee TS, Kim YB, Park KH, Kim JW. Catalytic activities of intracellular dimeric neopullulanase on cyclodextrin, acarbose, and maltose. Biotechnol. Appl. Bioc. 35: 27-34 (2002) https://doi.org/10.1042/BA20010052
  8. Kim MJ, Lee SB, Lee HS, Lee SY, Baek JS, Kim D, Moon TW, Robyt JF, Park KH. Comparative study of the inhibition of alphaglucosidase, alpha-amylase, and cyclomaltodextrin glucanosyltransferase by acarbose, isoacarbose, and acarviosine-glucose. Arch. Biochem. Biophys. 371: 277-283 (1999) https://doi.org/10.1006/abbi.1999.1423
  9. Park KH, Kim MJ, Lee HS, Han NS, Kim D, Robyt JF. Transglycosylation reactions of Bacillus stearothermophilus maltogenic amylase with acarbose and various acceptors. Carbohyd. Res. 313: 235-246 (1998) https://doi.org/10.1016/S0008-6215(98)00276-6
  10. Ruppin H, Hagel J, Feuerbach W, Schutt H, Piehl J, Hillebrand I, Bloom S, Domschke W. Fate and effects of the alpha-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study. Gastroenterology 95: 93-99 (1988) https://doi.org/10.1016/0016-5085(88)90295-8
  11. Cha HJ, Yoon HG, Kim YW, Lee HS, Kim JW, Kweon KS, Oh BH, Park KH. Molecular and enzymatic characterization of a maltogenic amylase that hydrolyzes and transglycosylates acarbose. Eur. J. Biochem. 253: 251-262 (1998) https://doi.org/10.1046/j.1432-1327.1998.2530251.x
  12. Kim JS, Cha SS, Kim HJ, Kim TJ, Ha NC, Oh ST, Cho HS, Cho MJ, Kim MJ, Lee HS, Kim JW, Choi KY, Park KH, Oh BH. Crystal structure of a maltogenic amylase provides insights into a catalytic versatility. J. Biol. Chem. 274: 26279-26286 (1999) https://doi.org/10.1074/jbc.274.37.26279
  13. Kim TJ, Park CS, Cho HY, Cha SS, Kim JS, Lee SB, Moon TW, Kim JW, Oh BH, Park KH. Role of the glutamate 332 residue in the transglycosylation activity of Thermus Maltogenic amylase. Biochemistry 39: 6773-6780 (2000) https://doi.org/10.1021/bi992575i
  14. Joo HJ, Kang MJ, Seo TJ, Kim HA, Yoo SJ, Lee SK, Lim HJ, Byun BH, Kim JI. The Hypoglycemic effect of Saururus chinensis Baill in animal models of diabetes mellitus. Food Sci. Biotechnol. 15: 413-417 (2006)
  15. Kang MJ, Kim JI, Kwon TW. Effect of cheonggukjang on blood glucose and lipid profile in neonatal streptozotocin-induced diabetic rats. Food Sci. Biotechnol. 12: 544-547 (2003)
  16. Lee SJ, Grosskopf I, Choi SY, Cooper AD. Chylomicron remnant uptake in the livers of mice expressing human apolipoproteins E3, E2 (Arg158$\rightarrow$Cys), and E3-Leiden. J. Lipid Res. 45: 2199-2210 (2004) https://doi.org/10.1194/jlr.M400284-JLR200
  17. Andersen G, Rose CS, Hamid YH, Drivsholm T, Borch-Johnsen K, Hansen TPedersen O. Genetic variation of the GLUT10 glucose transporter (SLC2A10) and relationships to type 2 diabetes and intermediary traits. Diabetes 52: 2445-2448 (2003) https://doi.org/10.2337/diabetes.52.9.2445
  18. Dawson PA, Mychaleckyj JC, Fossey SC, Mihic SJ, Craddock AL, Bowden DW. Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol. Genet. Metab. 74: 186-199 (2001) https://doi.org/10.1006/mgme.2001.3212
  19. Rogers S, Macheda ML, Docherty SE, Carty MD, Henderson MA, Soeller WC, Gibbs EM, James DE, Best JD. Identification of a novel glucose transporter-like protein-GLUT-12. Am. J. Physiol.-Endoc. M. 282: E733-738 (2002)
  20. Cooper AD. Hepatic uptake of chylomicron remnants. J. Lipid Res. 38: 2173-2192 (1997)
  21. Raffai RL, Hasty AH, Wang Y, Mettler SE, Sanan DA, Linton MF, Fazio S, Weisgraber KH. Hepatocyte-derived ApoE is more effective than non-hepatocyte-derived ApoE in remnant lipoprotein clearance. J. Biol. Chem. 278: 11670-11675 (2003) https://doi.org/10.1074/jbc.M212873200
  22. Paive L, Binsack R, Machodo UF. Chronic acarbose-feeding increases GLUT1 protein without changing intestinal glucose absorption function. Eur. J. Pharmacol. 434: 197-204 (2002) https://doi.org/10.1016/S0014-2999(01)01538-2
  23. Yu KC, Jiang Y, Chen W, Cooper AD. Evaluation of the components of the chylomicron remnant removal mechanism by use of the isolated perfused mouse liver. J. Lipid Res. 40: 1899-1910 (1999)
  24. Yu KC, Jiang Y, Chen W, Cooper AD. Rapid initial removal of chylomicron remnants by the mouse liver does not require hepatically localized apolipoprotein E. J. Lipid Res. 41: 1715-1727 (2000)